Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7456 to 7470 of 7707 results

  1. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

    In development [GID-TAG406] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued

  4. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued [GID-TAG387]

    Technology appraisal guidance
    Discontinued

  5. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

    Technology appraisal guidance
    Discontinued

  6. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued [GID-TAG403]

    Technology appraisal guidance
    Discontinued

  7. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued [GID-TAG409]

    Technology appraisal guidance
    Discontinued

  8. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued [GID-TAG383]

    Technology appraisal guidance
    Discontinued

  9. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued [GID-TAG369]

    Technology appraisal guidance
    Discontinued

  10. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development [GID-TA10843] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]

    Discontinued [GID-TA11421]

    Technology appraisal guidance
    Discontinued

  13. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued [GID-TA10316]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]

    Discontinued [GID-TA11024]

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]

    Discontinued [GID-TA11005]

    Technology appraisal guidance
    Discontinued